Centessa Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Saurabh Saha
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 24.1% |
| CEO tenure | 4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.5yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$161m |
| Jun 30 2024 | n/a | n/a | -US$157m |
| Mar 31 2024 | n/a | n/a | -US$138m |
| Dec 31 2023 | US$3m | US$652k | -US$151m |
| Sep 30 2023 | n/a | n/a | -US$157m |
| Jun 30 2023 | n/a | n/a | -US$173m |
| Mar 31 2023 | n/a | n/a | -US$212m |
| Dec 31 2022 | US$10m | US$621k | -US$216m |
| Sep 30 2022 | n/a | n/a | -US$234m |
| Jun 30 2022 | n/a | n/a | -US$220m |
| Mar 31 2022 | n/a | n/a | -US$197m |
| Dec 31 2021 | US$16m | US$573k | -US$381m |
Compensation vs Market: Saurabh's total compensation ($USD2.71M) is above average for companies of similar size in the German market ($USD1.55M).
Compensation vs Earnings: Saurabh's compensation has been consistent with company performance over the past year.
CEO
Saurabh Saha (48 yo)
4yrs
Tenure
US$2,705,874
Compensation
Dr. Saurabh Saha, M. D., Ph. D. serves as an Independent Director at Clarivate Plc since May 04, 2023. He serves as the Chief Executive Officer at Centessa Pharmaceuticals plc (formerly Centessa Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4yrs | US$2.71m | 0.17% € 3.7m | |
| Chief Administrative Officer | 3.8yrs | US$1.32m | 0.11% € 2.5m | |
| CFO and Principal Financial & Accounting Officer | less than a year | no data | no data | |
| Chief Technology & Quality Officer | 1.5yrs | no data | 0.058% € 1.3m | |
| Senior Vice President of Investor Relations & Corporate Communications | 2.6yrs | no data | no data | |
| General Counsel | 3.9yrs | no data | 0.023% € 525.5k | |
| Chief People Officer | 2.2yrs | no data | 0.054% € 1.2m | |
| Chief Business Officer | less than a year | US$3.31m | 0.062% € 1.4m | |
| President of the Orexin Program | less than a year | no data | no data | |
| Senior Vice President of Clinical Development & Oncology | 1.3yrs | no data | no data | |
| Senior Vice President of Clinical Development Operations | less than a year | no data | no data |
1.5yrs
Average Tenure
53yo
Average Age
Experienced Management: 260's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4yrs | US$2.71m | 0.17% € 3.7m | |
| Independent Non-Executive Chairman of the Board | 4.2yrs | no data | no data | |
| Independent Non-Executive Director | 3.9yrs | US$252.69k | 0% € 0 | |
| Independent Non-Executive Director | 4yrs | US$257.69k | 0% € 0 | |
| Independent Non-Executive Director | 4yrs | US$260.19k | 0% € 0 | |
| Independent Non-Executive Director | 3.9yrs | US$255.19k | 0% € 0 | |
| Independent Non-Executive Director | 3.7yrs | US$262.69k | 0% € 0 | |
| Independent Non-Executive Director | 2.5yrs | US$247.69k | 0% € 0 |
4.0yrs
Average Tenure
53yo
Average Age
Experienced Board: 260's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 07:17 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Centessa Pharmaceuticals plc is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |